PULM

Pulmatrix, Inc. (PULM) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Pulmatrix, Inc. is a biopharmaceutical company focused on inhaled therapeutic products using its proprietary iSPERSE™ technology. The company has paused clinical development of its product candidates (PUR3100, PUR1800, PUR1900) to explore monetization and strategic alternatives. On March 26, 2026, the company entered into a definitive Merger Agreement with Eos SENOLYTIX, Inc. ("Eos"). Upon closing, Eos stockholders would own approximately 94% of the combined company, while existing Pulmatrix stockholders would own approximately 6%.

Key Financial Metrics

Note: Financial figures are in thousands unless otherwise noted.

Material Changes vs. Prior Period

• Reduced Operating Loss: Net loss decreased by $636,000 (35%) compared to Q1 2025, driven primarily by a $539,000 reduction in General and Administrative (G&A) expenses. G&A expenses dropped from $1.828 million to $1.289 million, largely due to lower costs associated with registration statement filings in the prior year.
• Financing Activity: The company raised $1.0 million in gross proceeds from the sale of Series B Convertible Preferred Stock in connection with the Merger Agreement. This contrasts with zero financing proceeds in Q1 2025.
• Other Income: "Other income (expense), net" improved significantly from a loss of $80,000 in Q1 2025 to income of $108,000 in Q1 2026. This was influenced by the absence of a $66,000 fair value adjustment loss on warrants recorded in the prior year.
• Liquidity Position: Cash and cash equivalents decreased by approximately $4.4 million from the end of Q1 2025 to Q1 2026, despite the new financing, due to operating cash burn.

Outlook, Risks, and Management Commentary

• Going Concern Uncertainty: Management has expressed substantial doubt about the company's ability to continue as a going concern for one year beyond the filing date if the Merger with Eos is not consummated. The company anticipates its current cash position is sufficient only through the anticipated closing of the Merger.
• Merger Dependency: Future operations are highly dependent on the success of the Merger. If the transaction fails, the board may pursue dissolution and liquidation. The Merger is subject to stockholder approval and regulatory conditions.
• Restricted Cash: $700,000 of the proceeds from the Series B Preferred Stock issuance is classified as restricted cash. These funds are restricted until the Merger closes or the agreement is terminated.
• Development Status: All clinical development for PUR3100 (migraine), PUR1800 (COPD), and PUR1900 (fungal infections) remains on hold while the company seeks to license or monetize these assets.
• Risk Factors: Key risks include the failure to close the Merger, inability to secure additional funding, and the potential for dissolution if strategic alternatives are not realized.

Investor Verification Checklist

• Merger Approval Status: Verify the current status of stockholder votes and regulatory approvals required to close the Eos Merger.
• Cash Runway: Confirm the company's burn rate and whether the $3.3 million in unrestricted cash is sufficient to cover costs if the Merger is delayed or terminated.
• Series B Terms: Review the specific conversion terms and voting rights of the newly issued Series B Convertible Preferred Stock, which carries an 8% cumulative dividend.
• Asset Monetization: Monitor progress on licensing or selling the PUR3100, PUR1800, and PUR1900 assets, as these are the primary potential sources of future revenue outside the Merger.
• Legal Proceedings: Check for any new litigation related to the Merger Agreement or intellectual property disputes that could impede the transaction.